



Publications gateway number: GOV-12989

## Inactivated influenza vaccine Patient Group Direction (PGD)

This PGD is for the administration of inactivated influenza vaccine to individuals in accordance with the national influenza immunisation programme.

This PGD is for the administration of inactivated influenza vaccine by registered healthcare practitioners identified in [Section 3](#), subject to any limitations to authorisation detailed in [Section 2](#).<sup>1</sup>

Reference no: Inactivated influenza PGD  
Version no: v11.00  
Valid from: 1 September 2022  
Review date: 1 April 2023  
Expiry date: 1 April 2023

**The UK Health Security Agency (UKHSA) has developed this PGD to facilitate the delivery of publicly funded immunisation in England in line with national recommendations.**

Those using this PGD must ensure that it is organisationally authorised and signed in Section 2 by an appropriate authorising person, relating to the class of person by whom the product is to be supplied, in accordance with Human Medicines Regulations 2012 (HMR2012)<sup>2</sup>. **The PGD is not legal or valid without signed authorisation in accordance with [HMR2012 Schedule 16 Part 2](#).**

Authorising organisations must not alter, amend or add to the clinical content of this document (sections 4, 5 and 6); such action will invalidate the clinical sign-off with which it is provided. In addition, authorising organisations must not alter section 3 'Characteristics of staff'. Only sections 2 and 7 can be amended within the designated editable fields provided.

Operation of this PGD is the responsibility of commissioners and service providers. The final authorised copy of this PGD should be kept by the authorising organisation completing Section 2 for 8 years after the PGD expires if the PGD relates to adults only and for 25 years after the PGD expires if the PGD relates to children only, or adults and children. Provider organisations adopting authorised versions of this PGD should also retain copies for the periods specified above.

**Individual practitioners must be authorised by name, under the current version of this PGD before working according to it.**

Practitioners and organisations must check that they are using the current version of the PGD. Amendments may become necessary prior to the published expiry date. Current versions of PHE/UKHSA PGD templates for authorisation can be found from [Immune patient group direction \(PGD\) templates](#)

Any concerns regarding the content of this PGD should be addressed to:  
[immunisation@ukhsa.gov.uk](mailto:immunisation@ukhsa.gov.uk)

Enquiries relating to the availability of organisationally authorised PGDs and subsequent versions of this PGD should be directed to: your local screening and immunisation team |

<sup>1</sup> This PGD is not relevant to the national community pharmacy seasonal influenza vaccination advanced service which has its own PGD (see [Pharmacy Influenza Vaccination PGD](#))




<sup>2</sup> This includes any relevant amendments to legislation

## Change history

Version number	Change details	Date
V01.00 – V07.00	See earlier version of this PGD for change details.	18 August 2015 to 8 May 2019
V08.00	<p>PHE IM Influenza PGD amended to:</p> <ul style="list-style-type: none"> <li>• extend the characteristics of staff to include all registered practitioners legally able to work under PGD</li> <li>• include household contacts of those on the NHS Shielded Patient List, health and social care workers employed through Direct Payments or Personal Health Budgets and, subject to vaccine supply, extension of the programme to individuals from 50 years of age and children in routine age cohorts unable to receive LAIV</li> <li>• update the table of recommended inactivated influenza vaccines for the 2020 to 2021 season</li> <li>• update supplies section</li> <li>• remove reference to Fludax<sup>®</sup> brand which will not be supplied to UK this season and remove black triangle from Fluarix<sup>®</sup> Tetra</li> <li>• remove reference to barium sulphate which is no longer listed in the adjuvanted trivalent influenza influenza vaccine SPC as a residue of the manufacturing process</li> <li>• update additional information section</li> <li>• include minor rewording, layout and formatting changes for clarity and consistency with other PHE PGDs</li> </ul>	24 August 2020
V09.00	<p>PHE Inactivated Influenza PGD amended to:</p> <ul style="list-style-type: none"> <li>• include eligible cohorts for the 2021 to 2022 season</li> <li>• include the inactivated influenza vaccines for the 2021 to 2022 season</li> <li>• include minor rewording, layout and formatting changes for clarity and consistency with other PHE PGDs</li> </ul>	23 July 2021
V10.00	<p>Inactivated Influenza PGD amended to:</p> <ul style="list-style-type: none"> <li>• include primary care contractors (primary medical services, pharmaceutical services, primary dental services or general ophthalmic services) and their frontline staff, including locums</li> <li>• mention consent or 'best-interests' decision in accordance with the Mental Capacity Act 2005</li> <li>• update additional information and drug interactions sections</li> <li>• update for change of organisation from PHE to UKHSA</li> <li>• web addresses hyperlinked into body text for clarity and consistency with other UKHSA PGDs</li> </ul>	12 October 2021
V11.00	<p>Inactivated influenza PGD amended to:</p> <ul style="list-style-type: none"> <li>• include only eligible cohorts for the 2022 to 2023 season</li> <li>• include the inactivated influenza vaccines for the 2022 to 2023 season</li> <li>• remove the exclusion of 'individuals who are less than 2 years of age and have had a severe anaphylactic reaction to egg which has previously required intensive care' and update cautions and off-label section to advise egg-free cell-based influenza vaccine is offered off-label to these individuals in accordance with JCVI advice and the annual flu letter</li> <li>• include minor rewording, layout and formatting changes for clarity and consistency with other UKHSA PGDs</li> </ul>	8 August 2022

## 1. PGD development

This PGD has been developed by the following health professionals on behalf of the UKHSA:

Developed by:	Name	Signature	Date
<b>Pharmacist</b> (Lead Author)	<b>Jacqueline Lamberty</b> Lead pharmacist Medicines Governance Health Equity and Clinical Governance Directorate, UKHSA	 J.Y.LAMBERTY	9 August 2022
<b>Doctor</b>	Jamie Lopez-Bernal Consultant Epidemiologist, Immunisation and Vaccine Preventable Diseases Division, UKHSA		9 August 2022
<b>Registered Nurse</b> (Chair of Expert Panel)	David Green Nurse Consultant for Immunisation, Immunisation and Vaccine Preventable Diseases Division, UKHSA		9 August 2022

This PGD has been peer reviewed by the UKHSA Immunisations PGD Expert Panel in accordance with the UKHSA PGD Policy. It has been approved by the UKHSA Medicines Governance Group and ratified by the UKHSA Clinical Quality and Oversight Board.

### Expert Panel

Name	Designation
Nicholas Aigbogun	Consultant in Communicable Disease Control, Yorkshire and Humber Health Protection Team, UKHSA
Sarah Dermont	Clinical Project Coordinator and Registered Midwife, NHS Infectious Diseases in Pregnancy Screening Programme, NHS England (NHSE)
Ed Gardner	Advanced Paramedic Practitioner/Emergency Care Practitioner, Urgent/Unscheduled Care Lead, Proactive Care Lead
Michelle Jones	Principal Medicines Optimisation Pharmacist, Bristol North Somerset and South Gloucestershire Integrated Care Board
Elizabeth Lockett	Senior Screening and Immunisation Manager, NHSE South West
Vanessa MacGregor	Consultant in Communicable Disease Control, East Midlands Health Protection Team, UKHSA
Alison MacKenzie	Consultant in Public Health Medicine, Screening and Immunisation Lead, NHSE South West
Gill Marsh	Principal Screening and Immunisation Manager, NHSE North West
Lesley McFarlane	Lead Immunisation Nurse Specialist, Immunisation and Vaccine Preventable Diseases Division, UKHSA
Tushar Shah	Lead Pharmacy Advisor, NHSE London
Conall Watson	Consultant Epidemiologist, Immunisation and Vaccine Preventable Diseases Division, UKHSA


## 2. Organisational authorisations

The PGD is not legally valid until it has had the relevant organisational authorisation.

It is the responsibility of the organisation that has legal authority to authorise the PGD, to ensure that all legal and governance requirements are met. The authorising body accepts governance responsibility for the appropriate use of the PGD.

NHS England (South East) authorises this PGD for use by the services or providers listed below:

Authorised for use by the following organisations and/or services
All NHS England commissioned immunisation services within the NHS England South East Region.
Limitations to authorisation
This patient group direction (PGD) must only be used by the registered healthcare practitioners identified in Section 3 who have been named by their organisation to practice under it. The most recent in-date final version authorised by NHS England (South East) must be used.
This PGD includes vaccination of individuals across the national immunisation programme. Users of this PGD should note that where they are commissioned to immunise certain groups this PGD does not constitute permission to offer immunisation beyond the groups they are commissioned to immunise.

Organisational approval (legal requirement)			
Role	Name	Sign	Date
South East Regional Medical Director	Dr Vaughan Lewis		16 August 2022

Additional signatories according to locally agreed policy			
Role	Name	Sign	Date

Local enquiries regarding the use of this PGD may be directed to your local screening and immunisation team

Section 7 provides a practitioner authorisation sheet. Individual practitioners must be authorised by name to work to this PGD. Alternative practitioner authorisation sheets may be used where appropriate in accordance with local policy, but this should be an individual agreement or a multiple practitioner authorisation sheet as included at the end of this PGD.

### 3. Characteristics of staff

<p><b>Qualifications and professional registration</b></p>	<p>Practitioners must only work under this PGD where they are competent to do so. Practitioners working to this PGD must also be one of the following registered professionals who can legally supply and administer under a PGD (see <a href="#">Patient Group Directions: who can administer them</a>):</p> <ul style="list-style-type: none"> <li>• nurses and midwives currently registered with the Nursing and Midwifery Council (NMC)</li> <li>• pharmacists currently registered with the General Pharmaceutical Council (GPhC) (Note: This PGD is not relevant to the national community pharmacy seasonal influenza vaccination advanced service nor privately provided community pharmacy services)</li> <li>• chiropodists/podiatrists, dieticians, occupational therapists, orthoptists, orthotists/prosthetists, paramedics, physiotherapists, radiographers and speech and language therapists currently registered with the Health and Care Professions Council (HCPC)</li> <li>• dental hygienists and dental therapists registered with the General Dental Council</li> <li>• optometrists registered with the General Optical Council</li> </ul> <p>Practitioners must also fulfil all the <a href="#">Additional requirements</a>.</p> <p>Check <a href="#">Section 2 Limitations to authorisation</a> to confirm whether all the registered practitioners listed above have organisational authorisation to work under this PGD.</p>
<p><b>Additional requirements</b></p>	<p>Additionally, practitioners:</p> <ul style="list-style-type: none"> <li>• must be authorised by name as an approved practitioner under the current terms of this PGD before working to it</li> <li>• must have undertaken appropriate training for working under PGDs for supply/administration of medicines</li> <li>• must be competent in the use of PGDs (see <a href="#">NICE Competency framework</a> for health professionals using PGDs)</li> <li>• must be familiar with the vaccine product and alert to changes in the Summary of Product Characteristics (SPC), Immunisation Against Infectious Disease (the '<a href="#">Green Book</a>'), and national and local immunisation programmes</li> <li>• must have undertaken training appropriate to this PGD as required by local policy and in line with the <a href="#">National Minimum Standards and Core Curriculum for Immunisation</a>. For further information see <a href="#">Flu immunisation training recommendations</a></li> <li>• must be competent to undertake immunisation and to discuss issues related to immunisation</li> <li>• must be competent in the handling and storage of vaccines, and management of the cold chain</li> <li>• must be competent in the recognition and management of anaphylaxis</li> <li>• must have access to the PGD and associated online resources</li> <li>• should fulfil any additional requirements defined by local policy</li> </ul> <p><b>The individual practitioner must be authorised by name, under the current version of this PGD before working according to it.</b></p>
<p><b>Continued training requirements</b></p> <p>Continued over page</p>	<p>Practitioners must ensure they are up to date with relevant issues and clinical skills relating to immunisation and management of anaphylaxis, with evidence of appropriate Continued Professional Development (CPD).</p> <p>Practitioners should be constantly alert to any subsequent recommendations from UKHSA and/or NHSE and other sources of medicines information.</p>

**Continued training requirements**  
(continued)

Note: The most current national recommendations should be followed but a Patient Specific Direction (PSD) may be required to administer the vaccine in line with updated recommendations that are outside the criteria specified in this PGD.

#### 4. Clinical condition or situation to which this PGD applies

<p><b>Clinical condition or situation to which this PGD applies</b></p>	<p>Inactivated influenza vaccine is indicated for the active immunisation of individuals for the prevention of influenza infection, in accordance with the national immunisation programme and recommendations given in <a href="#">Chapter 19</a> of the Immunisation Against Infectious Disease: the ‘Green Book’, <a href="#">annual flu letter(s)</a> and subsequent correspondence/publications from UKHSA and/or NHSE.</p> <p>Note: This PGD does not cover the provision of occupational health schemes or peer-to-peer influenza immunisation (see NHS Specialist Pharmacy Service <a href="#">‘Written instruction</a> template for the administration of inactivated seasonal influenza vaccine as part of an occupational health scheme, which may include peer-to-peer immunisation’). This PGD covers NHS commissioned services only (see <a href="#">Criteria for inclusion</a> below for specified frontline staff without employer led occupational health schemes).</p>
<p><b>Criteria for inclusion</b></p> <p>Continued over page</p>	<p>For the 2022 to 2023 influenza season, influenza vaccine should be offered under the NHS influenza immunisation programme to the following groups:</p> <ul style="list-style-type: none"> <li>• individuals aged 65 years or over (including those becoming age 65 years by 31 March 2023)</li> <li>• healthy individuals aged 50 to 64 years (including those becoming age 50 years by 31 March 2023) eligible from 15 October 2022</li> <li>• individuals aged from 6 months to less than 50 years of age in a clinical risk group category listed in <a href="#">Chapter 19</a> of the Green Book such as those with:             <ul style="list-style-type: none"> <li>○ chronic (long-term) respiratory disease, such as asthma (that requires continuous or repeated use of inhaled or systemic steroids or with previous exacerbations requiring hospital admission), chronic obstructive pulmonary disease (COPD) or bronchitis</li> <li>○ chronic heart disease and vascular disease, such as heart failure</li> <li>○ chronic kidney disease at stage 3, 4 or 5</li> <li>○ chronic liver disease</li> <li>○ chronic neurological disease, such as Parkinson’s disease or motor neurone disease</li> <li>○ learning disability</li> <li>○ diabetes and adrenal insufficiency</li> <li>○ asplenia or dysfunction of the spleen</li> <li>○ a weakened immune system due to disease (such as HIV/AIDS) or treatment (such as cancer treatment)</li> <li>○ morbidly obese adults (aged from 16 years) with a BMI of 40kg/m<sup>2</sup> and above</li> </ul> </li> <li>• all pregnant women (including those women who become pregnant during the influenza season)</li> <li>• household contacts of immunocompromised individuals, specifically individuals who expect to share living accommodation on most days over the winter and, therefore, for whom continuing close contact is unavoidable</li> <li>• people living in long-stay residential care homes or other long-stay care facilities where rapid spread is likely to follow introduction of infection and cause high morbidity and mortality. This does not include, for instance, prisons, young offender institutions, university halls of residence or boarding schools</li> <li>• those who are in receipt of a carer’s allowance, or those who are the main carer of an older or disabled person whose welfare may be at risk if the carer falls ill</li> <li>• frontline staff without employer led occupational health schemes, employed:</li> </ul>



<p><b>Criteria for inclusion</b> (continued)</p>	<ul style="list-style-type: none"> <li>○ by a registered residential care or nursing home or registered domiciliary care provider, who are directly involved in the care of vulnerable individuals who are at increased risk from exposure to influenza</li> <li>○ by a voluntary managed hospice provider, who are directly involved in the care of vulnerable individuals who are at increased risk from exposure to influenza</li> <li>○ through Direct Payments (personal budgets) and/or Personal Health Budgets, such as Personal Assistants, to deliver domiciliary care to individuals</li> <li>● children eligible for the Routine Childhood Seasonal Influenza Vaccination Programme (aged 2 years to 10 years on 31 August 2022<sup>3</sup>) for whom live attenuated influenza vaccine (LAIV) is contraindicated (or is otherwise unsuitable, for instance due to the route or non-acceptance of porcine gelatine content)</li> </ul> <p>Additionally, in 2022 to 23, subject to sufficient influenza vaccine supplies being available nationally, the following additional cohorts will be offered influenza vaccination:</p> <ul style="list-style-type: none"> <li>● secondary school-aged children focusing on Years 7, 8 and 9 and any remaining vaccine will be offered to years 10 and 11, subject to vaccine availability (see <a href="#">Special considerations/Additional information</a>)</li> </ul>
<p><b>Criteria for exclusion<sup>4</sup></b></p>	<p>Individuals for whom valid consent, or 'best-interests' decision in accordance with the <a href="#">Mental Capacity Act 2005</a>, has not been obtained (for further information on consent see <a href="#">Chapter 2</a> of 'The Green Book').</p> <p>Individuals who:</p> <ul style="list-style-type: none"> <li>● are less than 6 months of age</li> <li>● are aged 2 years to under 18 years for whom live attenuated influenza vaccine (LAIV) is not contraindicated (or not otherwise unsuitable, for instance due to the route or non-acceptance of porcine gelatine content) and is available. Note: LAIV should be given to those aged 2 to under 18 years of age in preference to inactivated influenza vaccine where possible, see LAIV PGD</li> <li>● have had a confirmed anaphylactic reaction to a previous dose of the vaccine</li> <li>● have had a confirmed anaphylactic reaction to any component of the vaccine or residues from the manufacturing process<sup>5</sup> (other than ovalbumin – see <a href="#">Cautions</a>)</li> <li>● have received a complete dose of the recommended influenza vaccine for the current season, unless they are individuals aged 6 months to less than 9 years in a clinical risk group category listed in <a href="#">Chapter 19</a> of the 'Green Book' who should, in the first season they are vaccinated against influenza, receive a second dose of an appropriate influenza vaccine at least 4 weeks after the first dose</li> <li>● are suffering from acute severe febrile illness (the presence of a minor infection is not a contraindication for immunisation)</li> </ul>

<sup>3</sup> Some children in school year 6 might be outside of the age range specified (for example, if a child has been held back in school year(s)). It is acceptable to offer and deliver influenza immunisation to these children with their class peers under this PGD.

<sup>4</sup> Exclusion under this PGD does not necessarily mean the medication is contraindicated, but it would be outside its remit and another form of authorisation will be required

<sup>5</sup> Residues from the manufacturing process may include beta-propiolactone, cetyltrimethylammonium bromide (CTAB), formaldehyde, gentamicin, hydrocortisone, kanamycin, neomycin, octoxinol-9, octylphenol ethoxylate, polysorbate 80, sodium deoxycholate. Check the vaccine products SPC for details.

<p><b>Cautions including any relevant action to be taken</b></p>	<p>Individuals with a bleeding disorder may develop a haematoma at the injection site (see <a href="#">Route of Administration</a>).</p> <p>Individuals with a severe anaphylaxis to egg which has previously required intensive care can be immunised in any setting using an egg-free vaccine, for instance QIVc or QIVr. Individuals with less severe egg allergy can be immunised in any setting using an egg-free vaccine or an inactivated influenza vaccine with an ovalbumin content less than 0.12 micrograms/ml (equivalent to 0.06 micrograms for 0.5 ml dose). For details of the influenza vaccines available for the 2022 to 2023 season and their ovalbumin content see <a href="#">All influenza vaccines marketed in the UK for the 2022 to 2023 season</a>.</p> <p>Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.</p>
<p><b>Action to be taken if the patient is excluded</b></p>	<p>The risk to the individual of not being immunised must be taken into account. The indications for flu vaccination are not exhaustive, and the healthcare practitioner should consider the risk of flu exacerbating any underlying disease that an individual may have, as well as the risk of serious illness from flu itself. Where appropriate, such individuals should be referred, or a PSD obtained for immunisation.</p> <p>In case of postponement due to acute illness, advise when the individual can be vaccinated and ensure another appointment is arranged.</p> <p>Document the reason for exclusion and any action taken in the individual's clinical records.</p> <p>Seek appropriate advice from the local Screening and Immunisation Team, local Health Protection Team or the individual's clinician as required.</p> <p>Inform or refer to the GP or a prescriber as appropriate.</p>
<p><b>Action to be taken if the patient or carer declines treatment</b></p>	<p>Informed consent, from the individual or a person legally able to act on the person's behalf, must be obtained for each administration (see <a href="#">Additional Information</a>). Where a person lacks the capacity, in accordance with the <a href="#">Mental Capacity Act 2005</a>, a decision to vaccinate may be made in the individual's best interests. For further information on consent see <a href="#">Chapter 2</a> of '<a href="#">The Green Book</a>'.</p> <p>Advise the individual/parent/carer about the protective effects of the vaccine, the risks of infection and potential complications if not immunised.</p> <p>Document advice given and the decision reached.</p> <p>Inform or refer to the GP or a prescriber as appropriate.</p>
<p><b>Arrangements for referral for medical advice</b></p>	<p>As per local policy.</p>

## 5. Description of treatment

<p><b>Name, strength and formulation of drug</b></p>	<p>Inactivated influenza vaccine suspension in a pre-filled syringe, including:</p> <ul style="list-style-type: none"> <li>• adjuvanted quadrivalent influenza vaccine (aQIV)</li> <li>• cell-based quadrivalent influenza vaccine (QIVc)</li> <li>• egg-grown quadrivalent influenza vaccine (QIVe)</li> <li>• recombinant quadrivalent influenza vaccine (QIVr), Supemtek ▼</li> </ul> <p>Note: This PGD does not include high-dose quadrivalent influenza vaccine (QIV-HD) or trivalent influenza vaccines as these vaccines are not eligible for re-imburement under the NHS influenza vaccination programme for the 2022 to 2023 season, see <a href="#">All influenza vaccines marketed in the UK for the 2022 to 2023 season</a>.</p> <p>Some influenza vaccines are restricted for use in particular age groups. The SPC for individual products should always be referred to.</p> <p><b>Summary table of which influenza vaccines to offer (by age)</b></p> <table border="1" data-bbox="491 730 1390 1420"> <thead> <tr> <th data-bbox="496 734 730 824">Age</th> <th data-bbox="735 734 1385 824">Inactivated influenza vaccine to offer eligible individuals (see <a href="#">Criteria for inclusion</a>)</th> </tr> </thead> <tbody> <tr> <td data-bbox="496 831 730 1010">6 months to under 2 years</td> <td data-bbox="735 831 1385 1010">Offer QIVe For egg-allergic children under 2 years it is advised that QIVc may be offered off-label (see <a href="#">Cautions</a>)</td> </tr> <tr> <td data-bbox="496 1016 730 1106">2 years to under 18 years</td> <td data-bbox="735 1016 1385 1106">If LAIV is contraindicated (or it is otherwise unsuitable) offer QIVc<sup>6</sup></td> </tr> <tr> <td data-bbox="496 1113 730 1216">18 years to under 65 years</td> <td data-bbox="735 1113 1385 1216">Offer QIVc or QIVr If QIVc or QIVr are not available, offer QIVe</td> </tr> <tr> <td data-bbox="496 1223 730 1413">65 years<sup>7</sup> and over<sup>8</sup></td> <td data-bbox="735 1223 1385 1413">Offer aQIV or QIVr If aQIV or QIVr are not available, offer QIVc For those aged 64 who turn 65 years of age by 31 March 2023, aQIV may be offered off-label</td> </tr> </tbody> </table>	Age	Inactivated influenza vaccine to offer eligible individuals (see <a href="#">Criteria for inclusion</a> )	6 months to under 2 years	Offer QIVe For egg-allergic children under 2 years it is advised that QIVc may be offered off-label (see <a href="#">Cautions</a> )	2 years to under 18 years	If LAIV is contraindicated (or it is otherwise unsuitable) offer QIVc <sup>6</sup>	18 years to under 65 years	Offer QIVc or QIVr If QIVc or QIVr are not available, offer QIVe	65 years <sup>7</sup> and over <sup>8</sup>	Offer aQIV or QIVr If aQIV or QIVr are not available, offer QIVc For those aged 64 who turn 65 years of age by 31 March 2023, aQIV may be offered off-label
Age	Inactivated influenza vaccine to offer eligible individuals (see <a href="#">Criteria for inclusion</a> )										
6 months to under 2 years	Offer QIVe For egg-allergic children under 2 years it is advised that QIVc may be offered off-label (see <a href="#">Cautions</a> )										
2 years to under 18 years	If LAIV is contraindicated (or it is otherwise unsuitable) offer QIVc <sup>6</sup>										
18 years to under 65 years	Offer QIVc or QIVr If QIVc or QIVr are not available, offer QIVe										
65 years <sup>7</sup> and over <sup>8</sup>	Offer aQIV or QIVr If aQIV or QIVr are not available, offer QIVc For those aged 64 who turn 65 years of age by 31 March 2023, aQIV may be offered off-label										
<p><b>Legal category</b></p>	<p>Prescription only medicine (POM).</p>										
<p><b>Black triangle ▼</b></p>	<p>QIVc, QIVr and aQIV products are black triangle.</p> <p>The QIVe vaccine from Viatrix (formerly Mylan), Influvac® sub-unit Tetra is black triangle.</p> <p>This information was accurate at the time of writing. See product SPCs, available from the <a href="#">electronic medicines compendium</a> website, for indication of current black triangle status.</p>										
<p><b>Off-label use</b></p> <p>Continued over page</p>	<p>Where a vaccine is recommended off-label, as part of the consent process, consider informing the individual/parent/carer that the vaccine is being offered in accordance with national guidance but that this is outside the product licence.</p>										

<sup>6</sup> QIVe is suitable to offer to these children but as a second option. QIVe has not been procured by the UKHSA for this age group.

<sup>7</sup> Including those turning age 65 years by 31 March 2023

<sup>8</sup> JCVI recommended use of QIV-HD in this age group but this is not currently available in the UK market.

<p><b>Off-label use</b> (continued)</p>	<p>The aQIV is licensed for administration to individuals aged 65 years and over. It may be administered under this PGD to those aged 64 years and turning 65 years of age by 31 March 2023 in accordance with the recommendations for the national influenza immunisation programme for the 2022 to 2023 season (see Appendix C of the <a href="#">annual flu letter</a> dated 22 April 2022).</p> <p>QIVc is licensed for those aged from 2 years. QIVc, which is egg-free, can be administered under this PGD to egg allergic children aged 6 months to less than 2 years as advised by JCVI (see Appendix D of the <a href="#">annual flu letter</a> dated 22 April 2022).</p> <p>Vaccine should be stored according to the conditions detailed in the <a href="#">Storage</a> section below. However, in the event of an inadvertent or unavoidable deviation of these conditions refer to <a href="#">Vaccine Incident Guidance</a>. Where vaccine is assessed in accordance with these guidelines as appropriate for continued use this would constitute off-label administration under this PGD.</p> <p>Note: Different influenza vaccine products are licensed from different ages and should be administered within their licence when working to this PGD, unless permitted off-label administration is detailed above. Refer to products' SPCs, available from the <a href="#">electronic medicines compendium</a> website, and <a href="#">All influenza vaccines marketed in the UK for the 2022 to 2023 season</a> for more information.</p>
<p><b>Route / method of administration</b></p> <p>Continued over page</p>	<p>Administer by intramuscular injection, preferably into the deltoid region of the upper arm. The anterolateral aspect of the thigh is the preferred site for infants under 1 year old.</p> <p>Individuals on stable anticoagulation therapy, including individuals on warfarin who are up to date with their scheduled INR testing and whose latest INR was below the upper threshold of their therapeutic range, can receive intramuscular vaccination. A fine needle (23 gauge or 25 gauge) should be used for the vaccination, followed by firm pressure applied to the site (without rubbing) for at least 2 minutes. If in any doubt, consult with the clinician responsible for prescribing or monitoring the individual's anticoagulant therapy.</p> <p>Individuals with bleeding disorders may be vaccinated intramuscularly if, in the opinion of a doctor familiar with the individual's bleeding risk, vaccines or similar small volume intramuscular injections can be administered with reasonable safety by this route. If the individual receives medication/treatment to reduce bleeding, for example treatment for haemophilia, intramuscular vaccination can be scheduled shortly after such medication/treatment is administered. A fine needle (23 gauge or 25 gauge) should be used for the vaccination, followed by firm pressure applied to the site (without rubbing) for at least 2 minutes. The individual/parent/carer should be informed about the risk of haematoma from the injection.</p> <p>Influenza vaccines licensed for both intramuscular or subcutaneous administration may alternatively be administered by the subcutaneous route. Note: QIVc, QIVr and aQIV are not licensed for subcutaneous administration so should only be administered intramuscularly under this PGD.</p> <p>When administering at the same time as other vaccines care should be taken to ensure that the appropriate route of injection is used for all the vaccinations.</p> <p>The vaccines should be given at separate sites, preferably in different limbs. If given in the same limb, they should be given at least 2.5cm apart. The site at which each vaccine was given should be noted in the individual's records.</p>

<b>Route / method of administration</b> (continued)	<p>If aQIV needs to be administered at the same time as another vaccine, immunisation should be carried out on separate limbs.</p> <p>Shake vaccine before administration.</p> <p>Inspect visually prior to administration and ensure appearance is consistent with the description in the products SPC.</p> <p>The SPCs provide further guidance on administration and are available from the <a href="#">electronic medicines compendium</a> website.</p>
<b>Dose and frequency of administration</b>	<p>Single 0.5ml dose to be administered for the current annual flu season.</p> <p>Children in a clinical risk group aged 6 months to less than 9 years old who have not previously received any doses of influenza vaccine should be offered a second dose of vaccine at least 4 weeks later. The influenza vaccines are interchangeable, although the individual's age, recommended vaccine and vaccine licence should be considered (see <a href="#">Off-label use</a> section).</p> <p>JCVI has advised that when a choice of either a 0.25ml or 0.5ml dose is indicated in the SPC, the 0.5ml dose of inactivated influenza vaccine should be given to individuals from age 6 months because there is evidence that this dose is effective in young children.</p>
<b>Duration of treatment</b>	<p>Single 0.5ml dose for the current annual flu season (1 September 2022 to 31 March 2023).</p> <p>Children aged 6 months to less than 9 years old in a clinical risk group who have not received influenza vaccine previously should be offered a second dose of the vaccine at least 4 weeks later.</p>
<b>Quantity to be supplied / administered</b>	<p>Single dose of 0.5ml per administration.</p>
<b>Supplies</b>	<p>Centrally procured vaccine is available via ImmForm for children.</p> <p>Supplies for administration to adults should be ordered from the influenza vaccine manufacturers/wholesalers as in previous years.</p> <p>Protocols for the ordering, storage and handling of vaccines should be followed to prevent vaccine wastage (see the Green Book <a href="#">Chapter 3</a>).</p>
<b>Storage</b>	<p>Store at +2°C to +8°C. Do not freeze.</p> <p>Store in original packaging in order to protect from light.</p> <p>In the event of an inadvertent or unavoidable deviation of these conditions vaccine that has been stored outside the conditions stated above should be quarantined and risk assessed for suitability of continued off-label use or appropriate disposal. Refer to <a href="#">Vaccine Incident Guidance</a>.</p>
<b>Disposal</b>	<p>Equipment used for immunisation, including used vials, ampoules, or discharged vaccines in a syringe or applicator, should be disposed of safely in a UN-approved puncture-resistant 'sharps' box, according to local authority arrangements and guidance in the <a href="#">technical memorandum 07-01</a>: Safe management of healthcare waste (Department of Health, 2013).</p>
<b>Drug interactions</b>  Continued over page	<p>Immunological response may be diminished in those receiving immunosuppressive treatment, but it is important to still immunise this group.</p> <p>Because of the absence of data on co-administration of Shingrix<sup>®</sup> vaccine with adjuvanted influenza vaccine, it should not be routine to offer</p>

<p><b>Drug interactions</b> (continued)</p>	<p>appointments to give this vaccine at the same time as the adjuvanted influenza vaccine. Based on current information, scheduling should ideally be separated by an interval of at least 7 days to avoid incorrect attribution of potential adverse events. Where individuals attend requiring both vaccines, however, and require rapid protection or are considered likely to be lost to follow up, co-administration may still be considered.</p> <p>Inactivated influenza vaccine may be given at the same time as other vaccines (See <a href="#">Route / method of administration</a>). Where co-administration does occur, individuals should be informed about the likely timing of potential adverse events relating to each vaccine. If the vaccines are not given together, they can be administered at any interval, although separating the vaccines by a day or two will avoid confusion over systemic side effects.</p> <p>As all of the current COVID-19 vaccines are considered inactivated (including the non-replicating adenovirus vaccine), where individuals in an eligible cohort present having recently received COVID-19 vaccination, influenza vaccination should still be given.</p> <p>A detailed list of drug interactions is available in the SPC for each vaccine, which are available from the <a href="#">electronic medicines compendium</a> website.</p>
<p><b>Identification and management of adverse reactions</b></p>	<p>Pain, swelling or redness at the injection site, low-grade fever, malaise, shivering, fatigue, headache, myalgia and arthralgia are among the commonly reported symptoms after intramuscular vaccination. A small painless nodule (induration) may also form at the injection site. These symptoms usually disappear within 1 to 2 days without treatment.</p> <p>Immediate reactions such as urticaria, angio-oedema, bronchospasm and anaphylaxis can occur.</p> <p>A higher incidence of mild post-immunisation reactions has been reported with adjuvanted compared to non-adjuvanted influenza vaccines.</p> <p>The frequency of injection site pain and systemic reactions may be higher in individuals vaccinated concomitantly with inactivated influenza vaccine and pneumococcal polysaccharide vaccine (PPV23) compared to vaccination with influenza vaccine alone and similar to that observed with PPV23 vaccination alone. Influenza vaccine and PPV23 may be administered at the same visit or at any interval from each other.</p> <p>A detailed list of adverse reactions is available in the SPC for each vaccine, which are available from the <a href="#">electronic medicines compendium</a> website.</p>
<p><b>Reporting procedure of adverse reactions</b></p>	<p>Healthcare professionals and individuals/parents/carers are encouraged to report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the <a href="#">Yellow Card reporting scheme</a> or search for MHRA Yellow Card in the Google Play or Apple App Store.</p> <p>QIVe vaccine from Viatrix (formerly Mylan), QIVc, QIVr and aQIV are black triangle. Therefore, any suspected adverse reactions should be reported via the Yellow Card Scheme.</p> <p>Any adverse reaction to a vaccine should be documented in the individual's record and the individual's GP should be informed.</p>
<p><b>Written information to be given to patient or carer</b></p>	<p>Offer marketing authorisation holder's patient information leaflet (PIL) provided with the vaccine.</p>

<p><b>Patient advice / follow up treatment</b></p>	<p>Individuals should be advised regarding adverse reactions to vaccination and reassured that the inactivated vaccine cannot cause influenza. However, the vaccine will not provide protection for about 14 days and does not protect against other respiratory viruses that often circulate during the flu season.</p> <p>Immunosuppressed individuals should be advised that they may not make a full immune response to the vaccine. Therefore, consideration should be given to the influenza vaccination of their household contacts.</p> <p>Inform the individual/parent/carer of possible side effects and their management.</p> <p>The individual/parent/carer should be advised when to seek medical advice in the event of an adverse reaction.</p> <p>When applicable, advise the individual/parent/carer when to return for vaccination or when a subsequent vaccine dose is due.</p>
<p><b>Special considerations / additional information</b></p>	<p>Ensure there is immediate access to adrenaline (epinephrine) 1 in 1,000 injection and easy access to a telephone at the time of vaccination.</p> <p>Minor illnesses without fever or systemic upset are not valid reasons to postpone immunisation. If an individual is acutely unwell, immunisation may be postponed until they have fully recovered.</p> <p>For children under the age of 16 years, those assessed as Gillick competent can self-consent (for further information on consent see <a href="#">Chapter 2</a> of '<a href="#">The Green Book</a>').</p> <p>Individuals with learning disabilities may require reasonable adjustments to support vaccination (see <a href="#">Flu vaccinations: supporting people with learning disabilities</a>). A PSD may be required.</p> <p>The licensed ages for the 2022 to 2023 season influenza vaccines are:</p> <ul style="list-style-type: none"> <li>• QIVe licensed from 6 months of age</li> <li>• QIVc licensed from 2 years of age (see <a href="#">Off-label</a> section)</li> <li>• QIVr licensed from 18 years of age</li> <li>• aQIV licensed from 65 years of age (see <a href="#">Off-label</a> section)</li> </ul> <p>For 50 to 64 year olds, the advice of JCVI is the most vulnerable cohorts should be prioritised over the otherwise healthy 50 to 64 year olds and given the most effective vaccines available first, QIVr or QIVc where possible, while QIVe should be reserved for otherwise healthy 50 to 64 year olds. However, QIVe is suitable to offer as a second option for vulnerable cohorts.</p> <p>School aged children will be offered the flu vaccination through the school age immunisation service via school or community settings. Primary school aged children will be prioritised earlier in the season with secondary school aged children in years 7, 8 and 9 being invited later. Should vaccine supplies allow, further secondary school years may be included upon the instruction of the Commissioner. The date from which individuals in these additional cohorts may be vaccinated will be communicated directly with the Provider by their Commissioner.</p>
<p><b>Records</b></p> <p>Continued over page</p>	<p>Record:</p> <ul style="list-style-type: none"> <li>• that valid informed consent was given</li> <li>• name of individual, address, date of birth and GP with whom the individual is registered</li> <li>• name of immuniser</li> <li>• name and brand of vaccine</li> <li>• date of administration</li> </ul>

<p><b>Records</b> (continued)</p>	<ul style="list-style-type: none"> <li>• dose, form and route of administration of vaccine</li> <li>• quantity administered</li> <li>• batch number and expiry date</li> <li>• anatomical site of vaccination</li> <li>• advice given, including advice given if excluded or declines immunisation</li> <li>• details of any adverse drug reactions and actions taken</li> <li>• supplied via PGD</li> </ul> <p>Records should be signed and dated (or password controlled immuniser's record on e-records).</p> <p>All records should be clear, legible and contemporaneous.</p> <p>As a wide variety of influenza vaccines are available on the UK market each year, it is especially important that the exact brand of vaccine, batch number and site at which each vaccine is given is accurately recorded in the individual's records.</p> <p>It is important that vaccinations given either at a general practice or elsewhere (for example at antenatal clinics) are recorded on appropriate health records for the individual (using the appropriate clinical code) in a timely manner. If given elsewhere, systems should be in place to ensure a record of vaccination is returned to the individual's general practice to allow clinical follow up and to avoid duplicate vaccination.</p> <p>For pregnant women, also record immunisation in the hand held and electronic maternity record if available.</p> <p>A record of all individuals receiving treatment under this PGD should also be kept for audit purposes in accordance with local policy.</p>
-----------------------------------	--



## 6. Key references

<b>Key references</b>	<b>Inactivated influenza vaccination</b> <ul style="list-style-type: none"><li>• Immunisation Against Infectious Disease: The Green Book, <a href="https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book">Chapter 19</a>. Published 29 October 2020.</li><li>• Collection: Annual Flu Programme. Updated 26 July 2022 <a href="https://www.gov.uk/government/collections/annual-flu-programme">https://www.gov.uk/government/collections/annual-flu-programme</a></li><li>• The national flu immunisation programme 2022 to 2023: supporting letter. Published 22 April 2022. <a href="https://www.gov.uk/government/publications/national-flu-immunisation-programme-plan">https://www.gov.uk/government/publications/national-flu-immunisation-programme-plan</a></li><li>• Statement of amendments to annual flu letter – 21 July 2022 <a href="https://www.gov.uk/government/publications/national-flu-immunisation-programme-plan/statement-of-amendments-to-annual-flu-letter-21-july-2022">https://www.gov.uk/government/publications/national-flu-immunisation-programme-plan/statement-of-amendments-to-annual-flu-letter-21-july-2022</a></li><li>• Enhanced Service Specification, Seasonal influenza and vaccination programme 2022 to 2023. <a href="https://www.england.nhs.uk/gp/investment/gp-contract/">https://www.england.nhs.uk/gp/investment/gp-contract/</a></li><li>• All influenza vaccines marketed in the UK for the 2022 to 2023 season <a href="https://www.gov.uk/government/publications/influenza-vaccines-marketed-in-the-uk">https://www.gov.uk/government/publications/influenza-vaccines-marketed-in-the-uk</a></li><li>• Live attenuated influenza vaccine (LAIV) PGD <a href="https://www.gov.uk/government/publications/influenza-vaccine-fluenz-tetra-patient-group-direction-pgd-template">https://www.gov.uk/government/publications/influenza-vaccine-fluenz-tetra-patient-group-direction-pgd-template</a></li><li>• Written instruction for the administration of seasonal ‘flu vaccination. NHS Specialist Pharmacy Service. 22 June 2022 <a href="https://www.sps.nhs.uk/articles/written-instruction-for-the-administration-of-seasonal-flu-vaccination/">https://www.sps.nhs.uk/articles/written-instruction-for-the-administration-of-seasonal-flu-vaccination/</a></li><li>• Summary of Product Characteristics <a href="http://www.medicines.org.uk">www.medicines.org.uk</a></li><li>• Flu immunisation training recommendations. Updated 27 July 2021. <a href="https://www.gov.uk/government/publications/flu-immunisation-training-recommendations">https://www.gov.uk/government/publications/flu-immunisation-training-recommendations</a></li><li>• Flu Vaccinations: Supporting people with learning disabilities. Updated 25 September 2018. <a href="https://www.gov.uk/government/publications/flu-vaccinations-for-people-with-learning-disabilities">https://www.gov.uk/government/publications/flu-vaccinations-for-people-with-learning-disabilities</a></li></ul> <b>General</b> <ul style="list-style-type: none"><li>• Health Technical Memorandum 07-01: Safe Management of Healthcare Waste. Department of Health 20 March 2013 <a href="https://www.england.nhs.uk/publication/management-and-disposal-of-healthcare-waste-hm-07-01/">https://www.england.nhs.uk/publication/management-and-disposal-of-healthcare-waste-hm-07-01/</a></li><li>• Immunisation Against Infectious Disease: The Green Book. Chapter 2. Updated 18 June 2021. <a href="https://www.gov.uk/government/publications/consent-the-green-book-chapter-2">https://www.gov.uk/government/publications/consent-the-green-book-chapter-2</a></li><li>• National Minimum Standards and Core Curriculum for Immunisation Training. Published February 2018 <a href="https://www.gov.uk/government/publications/national-minimum-">https://www.gov.uk/government/publications/national-minimum-</a></li></ul>
-----------------------	---

Continued over page

<p><b>Key references</b> (continued)</p>	<p><a href="#">standards-and-core-curriculum-for-immunisation-training-for-registered-healthcare-practitioners</a></p> <ul style="list-style-type: none"> <li>• NICE Medicines Practice Guideline 2 (MPG2): Patient Group Directions. Published March 2017. <a href="https://www.nice.org.uk/guidance/mpg2">https://www.nice.org.uk/guidance/mpg2</a></li> <li>• NICE MPG2 Patient group directions: competency framework for health professionals using patient group directions. Updated March 2017. <a href="https://www.nice.org.uk/guidance/mpg2/resources">https://www.nice.org.uk/guidance/mpg2/resources</a></li> <li>• Patient Group Directions: who can use them. Medicines and Healthcare products Regulatory Agency. 4 December 2017. <a href="https://www.gov.uk/government/publications/patient-group-directions-pgds/patient-group-directions-who-can-use-them">https://www.gov.uk/government/publications/patient-group-directions-pgds/patient-group-directions-who-can-use-them</a></li> <li>• UKHSA Immunisation Collection <a href="https://www.gov.uk/government/collections/immunisation">https://www.gov.uk/government/collections/immunisation</a></li> <li>• Vaccine Incident Guidance <a href="https://www.gov.uk/government/publications/vaccine-incident-guidance-responding-to-vaccine-errors">https://www.gov.uk/government/publications/vaccine-incident-guidance-responding-to-vaccine-errors</a></li> </ul>
--	--

## 7. Practitioner authorisation sheet

**Inactivated Influenza PGD v11.00 Valid from: 1 September 2022 Expiry: 1 April 2023**

Before signing this PGD, check that the document has had the necessary authorisations in section 2. Without these, this PGD is not lawfully valid.

### Practitioner

By signing this PGD you are indicating that you agree to its contents and that you will work within it.

PGDs do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practise only within the bounds of their own competence and professional code of conduct.

I confirm that I have read and understood the content of this PGD and that I am willing and competent to work to it within my professional code of conduct.

Name	Designation	Signature	Date

### Authorising manager

I confirm that the practitioners named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of *insert name of organisation* for the above named health care professionals who have signed the PGD to work under it.

Name	Designation	Signature	Date

### Note to authorising manager

Score through unused rows in the list of practitioners to prevent practitioner additions post managerial authorisation.

This authorisation sheet should be retained to serve as a record of those practitioners authorised to work under this PGD